Erin Wright
Stock Analyst at Morgan Stanley
(4.40)
# 345
Out of 4,967 analysts
228
Total ratings
61.85%
Success rate
13.37%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDXX IDEXX Laboratories | Maintains: Overweight | $722 → $765 | $639.45 | +19.63% | 16 | Aug 15, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $16 → $17 | $20.72 | -17.95% | 9 | Aug 1, 2025 | |
| CVS CVS Health | Maintains: Overweight | $80 → $82 | $74.09 | +10.68% | 5 | Aug 1, 2025 | |
| HUM Humana | Maintains: Equal-Weight | $290 → $277 | $310.06 | -10.66% | 4 | Jul 31, 2025 | |
| ALGN Align Technology | Downgrades: Equal-Weight | $249 → $154 | $137.16 | +12.28% | 23 | Jul 31, 2025 | |
| ELV Elevance Health | Maintains: Overweight | $428 → $316 | $322.33 | -1.96% | 3 | Jul 18, 2025 | |
| MCK McKesson | Maintains: Overweight | $770 → $810 | $691.62 | +17.12% | 8 | Jul 16, 2025 | |
| PSX Phillips 66 | Maintains: Equal-Weight | $122 → $128 | $133.84 | -4.36% | 1 | Jul 16, 2025 | |
| COR Cencora | Maintains: Equal-Weight | $313 → $330 | $294.85 | +11.92% | 1 | Jul 16, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $181 → $190 | $149.55 | +27.05% | 12 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $364 → $266 | $183.25 | +45.16% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $26 | $36.69 | -29.13% | 23 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $25 | $23.89 | +4.65% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $379 → $390 | $300.72 | +29.69% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3.5 → $3.2 | $3.03 | +5.61% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 → $13 | $17.85 | -27.17% | 11 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $243 → $238 | $152.88 | +55.68% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $13.81 | +66.55% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $178.70 | -3.75% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $68.39 | -4.96% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $308.80 | +90.09% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $273.78 | +9.58% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $13.29 | +216.03% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $203.79 | +41.32% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $161.25 | +118.29% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $2.37 | +1,756.54% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $471.93 | -61.65% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $55.29 | -69.25% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $39.44 | +206.80% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $487.53 | +18.97% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $10.66 | +228.33% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $177.84 | +15.27% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $22.34 | -50.76% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $183.74 | -14.55% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $25.89 | +46.77% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $5.33 | +218.95% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $452.50 | -31.93% | 1 | Oct 25, 2017 |
IDEXX Laboratories
Aug 15, 2025
Maintains: Overweight
Price Target: $722 → $765
Current: $639.45
Upside: +19.63%
Envista Holdings
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $20.72
Upside: -17.95%
CVS Health
Aug 1, 2025
Maintains: Overweight
Price Target: $80 → $82
Current: $74.09
Upside: +10.68%
Humana
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $290 → $277
Current: $310.06
Upside: -10.66%
Align Technology
Jul 31, 2025
Downgrades: Equal-Weight
Price Target: $249 → $154
Current: $137.16
Upside: +12.28%
Elevance Health
Jul 18, 2025
Maintains: Overweight
Price Target: $428 → $316
Current: $322.33
Upside: -1.96%
McKesson
Jul 16, 2025
Maintains: Overweight
Price Target: $770 → $810
Current: $691.62
Upside: +17.12%
Phillips 66
Jul 16, 2025
Maintains: Equal-Weight
Price Target: $122 → $128
Current: $133.84
Upside: -4.36%
Cencora
Jul 16, 2025
Maintains: Equal-Weight
Price Target: $313 → $330
Current: $294.85
Upside: +11.92%
Cardinal Health
Jul 16, 2025
Maintains: Overweight
Price Target: $181 → $190
Current: $149.55
Upside: +27.05%
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $364 → $266
Current: $183.25
Upside: +45.16%
Jun 25, 2025
Maintains: Equal-Weight
Price Target: $21 → $26
Current: $36.69
Upside: -29.13%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $23.89
Upside: +4.65%
May 5, 2025
Maintains: Overweight
Price Target: $379 → $390
Current: $300.72
Upside: +29.69%
Apr 17, 2025
Maintains: Underweight
Price Target: $3.5 → $3.2
Current: $3.03
Upside: +5.61%
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $17.85
Upside: -27.17%
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $152.88
Upside: +55.68%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $13.81
Upside: +66.55%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $178.70
Upside: -3.75%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $68.39
Upside: -4.96%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $308.80
Upside: +90.09%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $273.78
Upside: +9.58%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $13.29
Upside: +216.03%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $203.79
Upside: +41.32%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $161.25
Upside: +118.29%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $2.37
Upside: +1,756.54%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $471.93
Upside: -61.65%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $55.29
Upside: -69.25%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $39.44
Upside: +206.80%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $487.53
Upside: +18.97%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $10.66
Upside: +228.33%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $177.84
Upside: +15.27%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $22.34
Upside: -50.76%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $183.74
Upside: -14.55%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $25.89
Upside: +46.77%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $5.33
Upside: +218.95%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $452.50
Upside: -31.93%